Search Within

Sydney X Lu

Formats
  1. Meeting Abstract (58)
  2. Journal Article (39)
  3. Research Letter (2)
  4. Review (1)
Groups
  1. Department of Medicine (100)
  2. Hematologic Malignancies, Division of (100)
  3. Center for Hematologic Malignancies (99)
  4. GSK Faculty (71)
  5. Executive Committee, Center for Hematologic Malignancies (70)
  6. Sloan Kettering Institute Postdocs (59)

More Groups

People
  1. Marcel Van Den Brink (45)
  2. David Suh (33)
  3. Alexander Lesokhin (32)
  4. Malin Hultcrantz (32)
  5. Neha Korde (31)
  6. Odette Smith (31)

More People

Years
  1. 2025 (1)
  2. 2023 (1)
  3. 2022 (11)
  4. 2021 (12)
  5. 2020 (11)
  6. 2019 (11)

More Years

Publications
  1. Blood (43)
  2. Biology of Blood and Marrow Transplantation (12)
  3. Clinical Lymphoma, Myeloma and Leukemia (4)
  4. Journal of Clinical Oncology (4)
  5. Journal of Immunology (3)
  6. Bone Marrow Transplantation (2)

More Publications

Publishers
  1. American Society of Hematology (43)
  2. Elsevier Inc. (17)
  3. Nature Publishing Group (10)
  4. American Society of Clinical Oncology (4)
  5. The American Association of Immunologists, Inc (3)
  6. American Association for Cancer Research (2)

More Publishers

Results (100)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ZRSR2 mutation induced minor intron retention drives MDS and diverse cancer predisposition via aberrant splicing of LZTR1
    Meeting Abstract

    Inoue, D.; Polaski, J. T.; Taylor, J.; Castel, P.; Chen, S.; Kobayashi, S.; Hogg, S. J.; Hayashi, Y.; Pineda, J. M. B.; Penson, A. V.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Accelerated single cell seeding in relapsed multiple myeloma
    Journal Article

    Landau, H. J.; Yellapantula, V.; Diamond, B. T.; Rustad, E. H.; Maclachlan, K. H.; Gundem, G.; Medina-Martinez, J.; Arango Ossa, J.; Levine, M. F.; Zhou, Y.; more...
    Nature Communications (2020)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma
    Journal Article

    Eveillard, M.; Rustad, E.; Roshal, M.; Zhang, Y.; Ciardiello, A.; Korde, N.; Hultcrantz, M.; Lu, S.; Shah, U.; Hassoun, H.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Modern treatments and future directions for newly diagnosed multiple myeloma patients
    Review

    Lu, S. X.
    Best Practice and Research: Clinical Haematology (2020)

    Fulltext@MSK | Save
  • Novel alterations in CSF1R, RET, and other diverse kinases in the histiocytoses with biochemical and structural insights into their mechanisms of activation
    Meeting Abstract

    Durham, B.; Lopez-Rodrigo, E.; Picarsic, J.; Abramson, D.; Rotemberg, V.; De Munck, S.; Pannecoucke, E.; Lu, S.; Pastore, A.; Mandelker, D.; more...
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis
    Meeting Abstract

    Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma
    Meeting Abstract

    Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • MALDI-TOF mass spectrometry in serum for the follow-up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
    Meeting Abstract

    Eveillard, M.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Smith, E. L.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Korde, N.; Landgren, O.; more...
    Blood (2019)

    Fulltext@MSK | Save